SentiSense
Ctrl+K
Quick tip: Press
to search stocks
A
ABBV
AbbVie Inc.
$219.68
-5.69 (-2.52%)
Summary
Stories
News
Metrics
Fundamentals
Holders
Full institutional holders data is a Pro feature
UpgradeInstitutional Holders
3785
tracked filers
Total Institutional Value
$162.9B
3785 holders tracked
Report Date
Q4 2025
SEC 13F-HR filing
Notable changes (1)
| Holder | Category | Shares | Value | Weight | Change |
|---|---|---|---|---|---|
VANGUARD GROUP INC | Index Fund | 160.3M | $37.1B | -- | +12323.0% |
STATE STREET CORP | Index Fund | 79.8M | $18.5B | -- | -0.3% |
GEODE CAPITAL MANAGEMENT, LLC | Index Fund | 35.7M | $8.2B | -- | +3.1% |
Capital Research Global Investors | Mutual Fund | 25.2M | $5.8B | -- | -0.1% |
NORGES BANK | Sovereign Wealth | 23.0M | $4.5B | -- | -0.6% |
Data source: SEC EDGAR 13F-HR filings
Company Profile
Symbol
ABBV
Market Cap
$398.49B
IPO Date
Dec 10, 2012
CEO
Robert A. Michael
Employees
57,000
Sector
--
Industry
PHARMACEUTICAL PREPARATIONS
Country
United States
Exchange
--
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Read MoreSimilar Stocks
GILD
Gilead Sciences, Inc.
$144.99
-0.15%
REGN
Regeneron Pharmaceuticals, Inc.
$745.77
-0.11%
JNJ
Johnson & Johnson
$241.52
-0.21%
BMY
Bristol Myers Squibb Company
$59.08
+0.22%
AMGN
Amgen Inc.
$366.21
-0.43%